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Background: Dyslipidemia is a risk factor for cardiovascular disease, with elevated low-density lipoprotein cholesterol
(LDL-C) and decreased high-density lipoprotein cholesterol (HDL-C) recognized as risk factors for acute coronary events.
Studies suggest an association between low cholesterol levels and poor outcomes in acute sepsis. We sought to
determine the relationship between baseline cholesterol levels and long-term rates of sepsis.
Methods: We used data from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort, a
population-based cohort of 30,239 community-dwelling adults. The primary outcome was first sepsis event, defined
as hospitalization for an infection with the presence of ≥2 systemic inflammatory response syndrome criteria
(abnormal temperature, heart rate, respiratory rate, white blood cell count) during the first 28 hours of hospitalization.
Cox models assessed the association between quartiles of HDL-C or LDL-C and first sepsis event, adjusted for
participant demographics, health behaviors, chronic medical conditions, and biomarkers.
Results: We included 29,690 subjects with available baseline HDL-C and LDL-C. There were 3423 hospitalizations for
serious infections, with 1845 total sepsis events among 1526 individuals. Serum HDL-C quartile was not associated with
long-term rates of sepsis (hazard ratio (HR) (95% CI): Q1 (HDL-C 5–40 mg/dl), 1.08 (0.91–1.28); Q2 (HDL-C 41–49 mg/dl),
1.06 (0.90–1.26); Q3 (HDL-C 50–61 mg/dl), 1.04 (0.89–1.23); Q4, reference). However, compared with the highest quartile
of LDL-C, low LDL-C was associated with higher rates of sepsis (Q1 (LDL-C 3–89 mg/dl), 1.30 (1.10–1.52); Q2 (LDL-C
90–111 mg/dl), 1.24 (1.06–1.47); Q3 (LDL-C 112–135 mg/dl), 1.07 (0.91–1.26); Q4, reference).
Conclusion: Low LDL-C was associated with higher long-terms rates of community-acquired sepsis. HDL-C level was
not associated with long-term sepsis rates.
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One of the greatest accomplishments for preventive medi-
cine has been the recognition and treatment of hyperlipid-
emia to prevent coronary artery disease (CAD). At the
forefront has been the institution of HMG-CoA reductase
inhibitor (statin) drug therapy to lower low-density
lipoprotein cholesterol (LDL-C) to target levels with
significant benefit [1]. More controversial, however, has
been the association between lower levels of high-density
lipoprotein cholesterol (HDL-C) and increased risk of* Correspondence: Hwang@uabmc.edu
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become trapped in the subendothelial space of human
artery cell walls and attract inflammatory cells. Generally,
HDL-C is protective because it transfers LDL-C to the
liver and adrenal glands and facilitates its elimination in
the intestinal tract. HDL-C also has several antioxidant
and anti-inflammatory properties which can help prevent
LDL-C oxidation and inflammatory cell migration. The
landmark Framingham study demonstrated that low
HDL-C was a risk factor for CAD death in both males
and females [2]. However, recent studies found no
additional benefit to raising serum HDL-C levels with
medications in patients with optimized LDL-C already on
statins [3].le is distributed under the terms of the Creative Commons Attribution 4.0
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may also play an important role in combating sepsis, the
syndrome of dysregulated response to microbial infection.
Sepsis results in approximately 570,000 annual emergency
department (ED) visits in the United States [4]. Nearly
215,000 patients die from sepsis each year [5] and sepsis
has an estimated cost of $16.7 billion annually in the
United States alone [6]. The most compelling evidence for
the role of lipids in protection against sepsis involves
HDL-C. There are several mechanisms by which HDL-C
has been shown to be protective in sepsis, including bac-
terial toxin binding and disposal [7, 8], monocyte suppres-
sion, macrophage and dendritic cell migration, release of
inflammatory cytokines [9, 10], and inhibition of vascular
and intercellular adhesion molecule expression [11]. All of
these processes can lead to dysregulated inflammation
and endothelial injury, which can result in the clinical
manifestations of organ damage and death. Low HDL-C
levels have also been associated with poor sepsis outcomes
[12–14]. In addition, LDL-C has been shown to facilitate
bacterial toxin clearance in sepsis [15]. Lagrost et al. [16]
demonstrated that lower baseline total cholesterol levels
were present in patients who developed sepsis after
cardiac surgery.
In prior studies, we have demonstrated that cardiovas-
cular disease is a risk factor for incident sepsis events
[17]. The association between baseline cholesterol and
rates of sepsis remains unknown. As with CAD, a rela-
tionship between cholesterol and sepsis could provide an
opportunity for potentially reducing an individual’s long-
term risk through targeting of particular lipids. In this
study, we sought to determine the association between
baseline lipid levels and long-term rates of sepsis among
community-dwelling adults in the Reasons for Geo-




We performed a prospective cohort study using data
from the REGARDS study, a national population-based
longitudinal cohort.
Data source
REGARDS is a 30,239-participant cohort study of
community-dwelling adults ≥ 45 years of age. The cohort
recruited participants from 2003 to 2007 [18]. The
cohort is 45% male, 41% African American, and 69%
aged >60 years. The study oversampled Black individuals
and those living in the southeastern United States, with
21% of the cohort originating from the coastal plains of
North Carolina, South Carolina, and Georgia (the
“stroke buckle”), and 35% from the remainder of North
Carolina, South Carolina, and Georgia plus Tennessee,Mississippi, Alabama, Louisiana, and Arkansas (the
“stroke belt”).
Baseline data obtained upon participant enrollment
included sociodemographics, health behaviors, chronic
medical conditions, as well as information on diet,
family history, psychosocial factors, and prior residences.
In addition, blood and urine specimens were obtained
from each participant. The study contacts participants
every 6 months to determine the date, location, and
reason for all hospitalizations.
Identification of sepsis events
We identified all hospitalizations attributed by participants
to a serious infection; for example, pneumonia, pyelo-
nephritis, urinary tract infection, diverticulitis, meningitis,
and cellulitis, among others. Two trained research as-
sistants independently conducted a structured review
of all retrieved medical records, including ED phys-
ician and nursing, admission, progress and discharge
notes, laboratory reports, vital sign tables, and radi-
ology reports. We reviewed records for the first
28 hours of hospitalization to allow for ED treatment
plus one full day of hospitalization. Sepsis events
were defined as a hospitalization for an infection with
the presence of ≥2 systemic inflammatory response
syndrome (SIRS) criteria (temperature <36 or >38 °C,
heart rate >90 beats per minute, respiratory rate >20
breaths per minute or PaCO2 < 32 mmHg, white
blood cell count <4000 or >12,000 cell/mm3) during the
first 28 hours of hospitalization. We did not consider
sepsis events occurring at later points of hospitalization.
We assessed sepsis events occurring over a 10-year time
period from January 1, 2003 through December 31, 2012.
Participant and hospitalization characteristics
Participant characteristics were determined during the
initial interview and in-home visit. Demographics in-
cluded age, race, sex, income, education, and geographic
location. Race was defined as White or Black/African
American, and was self-reported. Income was divided into
four categories (<$20,000, $20,000–34,000, $35,000–
74,000, ≥$75,000). Education categories included less than
high school, high school graduate, some college, and col-
lege or higher. Geographic region included the “stroke
buckle” (coastal plains of North Carolina, South Carolina,
and Georgia), the “stroke belt” (remainder of North
Carolina, South Carolina, and Georgia plus Tennessee,
Mississippi, Alabama, Louisiana, and Arkansas), and non-
belt. Health behaviors included cigarette smoking
(current, past, never) and alcohol use (moderate use (1
drink per day for women or 2 drinks per day for men),
heavy use (>1 drink per day for women and >2 drinks per
day for men) as per the National Institute on Alcohol
Abuse and Alcoholism classification).
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diabetes, hypertension, obesity, and stroke. Participants
self-reported history of cancer, myocardial infarction, or
stroke. CAD included a history of myocardial infarction
or electrocardiogram evidence of prior MI [19]. Dia-
betes was defined as fasting glucose ≥126 mg/L (or
glucose ≥200 mg/L for those not fasting) or the use of in-
sulin or oral hypoglycemic agents. Hypertension included
systolic blood pressure ≥ 140 mmHg, diastolic blood pres-
sure ≥ 90 mmHg, or the reported use of antihypertensive
agents. Obesity included a body mass index ≥ 30 kg/m2 or
waist circumference >102 cm for males or >88 cm for
females.
REGARDS did not collect information on pulmonary
conditions such as asthma and chronic obstructive pul-
monary disease. Therefore, we defined participant use of
pulmonary medications as a surrogate for chronic lung dis-
ease. Obtained from each participant’s medication inven-
tory, pulmonary medications included beta-2 adrenergic
agonists, leukotriene inhibitors, inhaled corticosteroids,
combination inhalers, and other pulmonary medications
such as ipratropium, cromolyn, aminophylline, and theo-
phylline. Statin use was defined in a similar manner, with
specific statins reported by subjects including atorvastatin,
fluvastatin, lovastatin, pravastatin, rosuvastatin, and simva-
statin. In order to account for medication adherence, we
also obtained participant responses to the four-question
version of the Morisky Medication Adherence Scale, which
provides a measure of individual compliance with medica-
tion use (scale ranges from 0 to 4, with 0 indicating good
adherence and 4 indicating poor adherence) [20].
We used data on biomarkers obtained for all subjects,
including high-sensitivity C-reactive protein (hs-CRP),
cystatin C, urinary albumin-to-creatinine ratio (ACR),
and estimated glomerular filtration rate (eGFR). Study
personnel collected blood and urine samples from all
REGARDS participants at subjects’ homes following a
10–12-hour fast. Samples were centrifuged to separate
serum or plasma within 2 hours of collection and
shipped overnight on ice packs to the laboratories at the
University of Vermont. On arrival, study personnel
centrifuged the samples at 30,000 × g and 4 °C. The
samples were either analyzed (general chemistries) im-
mediately or stored at −80 °C.
Functional status measures included the 12-Item Short
Form Health Survey (SF-12) physical composite score
(PCS) in addition to self-reported physical activity and
exhaustion. Consistent with established definitions, we
defined physical weakness as PCS < 75, low weekly
physical activity as responses of “almost never” or
“never” to the question “How many times per week do
you engage in intense physical activity, enough to work
up a sweat?,” and exhaustion as responses of “a little of
the time” or “none of the time” to the question “Howmuch of the time during the past 4 weeks did you have
energy?” [21–23].
Among participants hospitalized with sepsis, we identi-
fied several hospitalization characteristics via chart review
of available clinical data. We identified sepsis events with
elevated Sequential (sepsis-related) Organ Failure Assess-
ment (SOFA) score (≥2 points) using established criteria
[24, 25]. We also identified admission destination and in-
hospital mortality.
Primary exposure
Serum total cholesterol, HDL-C, and triglyceride levels
were directly measured from serum samples. LDL-C was
calculated using the Friedewald formula from total
cholesterol, HDL-C, and triglyceride [26]. Our primary
exposures were HDL-C and LDL-C quartiles. We also
classified lipid levels using established clinical cutoff
values for HDL-C (<40, 40–59, and ≥60 mg/dl) and
LDL-C (<130, 130–159, and ≥160 mg/dl) [1]. We also
analyzed lipid values as continuous variables and as per-
centages of total cholesterol (per standard deviation
increase).
Data analysis
We compared baseline participant characteristics across
HDL-C and LDL-C quartiles using Pearson chi-square
tests of association and t tests of equal means for cat-
egorical and continuous variables, respectively. Because
we observed visual trends in biomarker levels based on
lipid level quartiles, we specified tests for linear trend
using modified Poisson regression for a common out-
come, including abnormal biomarker as the dependent
variable with HDL-C or LDL-C quartile as the independ-
ent variable.
In order to determine the association between LDL-C
and HDL-C and rates of sepsis, we fit a series of Cox
proportional hazards regression models, fitting time to
first sepsis event as the outcome and lipid quartile as the
exposure. We defined person-time at risk as days from
first interview to first sepsis hospitalization. Participants
without a sepsis event were censored at the earliest of
last follow-up interview, death, or December 31, 2012.
We sequentially adjusted the model for subject demo-
graphics (age, sex, race, education, income, geographic
region), health behaviors (smoking or alcohol use),
chronic medical conditions (cancer, chronic lung disease,
CAD, diabetes, hypertension, obesity, stroke, statin use,
Morisky adherence index), biomarkers (hs-CRP, cystatin
C, ACR, eGFR), and functional status (weakness, exhaus-
tion, low physical activity). We additionally examined
HDL-C and LDL-C using relevant clinical cutoff values
and as standardized continuous variables, both in their
original forms and as a percentage of total cholesterol. We
also stratified the analysis by statin use, generating new
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Lastly, we performed a sensitivity analysis in which several
measures (body mass index, hs-CRP, cystatin C, ACR, and
eGFR) were included as continuous variables.
Because of the substantial number of missing values
for select variables included in our final model (HDL-C
4.8%, LDL-C 6.1%, cystatin C 6.8%, hs-CRP 6.4%, ACR
4.7%, eGFR 4.3%), we performed all modeling using mul-
tiple imputation. We implemented multiple imputation
using chained equations with the Stata ‘MI’ suite, gener-
ating 10 imputed data sets and pooling estimates using
Rubin’s rules [27, 28]. Patterns of missingness were
examined in order to ensure that the assumption of
randomness was met and the imputation model included
all variables from the final analytic model, in addition to
the Nelson–Aalen cumulative hazard function (a com-
mon approach for incorporating the outcome measure)
[29].We ultimately reported adjusted hazard ratios and
Kaplan–Meier failure functions after pooling across im-
putations. All analyses were performed using Stata 13.1
(Statacorp, College Station, TX, USA).
Results
Of the 30,239 total REGARDS participants, we included
29,690 with complete follow-up information. Among
this group, there were 3423 hospitalizations for serious
infections, with 1845 total sepsis events among 1526
individuals. Median follow-up time was 3.6 years (IQR
1.8–5.6) for participants with first sepsis events and
6.6 years (IQR 5.2–8.1) for censored participants.
Baseline participant characteristics by lipid level quartile
are presented in Table 1. Compared with the highest
quartile, participants in the lowest HDL-C quartile were
more likely to be male, White, have less than a high school
education, reside in the stroke belt, be a current smoker,
and use no alcohol. This group was also more likely to
have a number of chronic medical conditions and bio-
marker abnormalities, including CAD, diabetes, hyperten-
sion, obesity, stroke, statin use, elevated hs-CRP/cystatin-
C/ACR, and reduced eGFR. Similarly, compared with the
highest quartile, participants in the lowest quartile for
LDL-C were more likely to be male and White; also ex-
periencing disproportionate CAD, diabetes, hypertension,
stroke, statin use, elevated cystatin C/ACR, and reduced
eGFR. In contrast to HDL-C, participants in the lowest
LDL-C quartile were less likely to have elevated hs-CRP
compared with the highest quartile. Significant linear
trends across quartiles were observed for all biomarkers
examined (p < 0.001).
Sepsis incidence differed substantially across HDL-C
and LDL-C quartiles, with the highest incidence
observed in the lowest quartile and the lowest incidence
in the highest quartile for both lipid types (Table 2). The
most common infection types associated with first sepsisepisode were pneumonia (39.4%), kidney and urinary
tract (17.0%), and abdominal infections (15.1%). Pneu-
monia was more common for participants in the highest
quartile of HDL-C compared with the lowest, while
abdominal infections were more common in the lowest
quartile. For LDL-C, kidney and urinary tract infections
were more common in the lowest quartile compared
with the highest. Compared with the higher quartiles,
the lowest quartiles of HDL-C and LDL-C had higher
proportions of individuals with elevated SOFA scores.
In unadjusted analyses, the lowest quartiles for both
HDL-C and LDL-C were associated with increased
sepsis rates (Table 3 and Fig. 1). After adjustment for
demographics, health behaviors, and chronic medical
conditions, HDL-C quartile remained associated with
long-term risk of sepsis. However, after the addition of
biomarkers to the model, HDL-C was no longer associ-
ated with rates of sepsis. Similarly, HDL-C defined using
clinical cutoff values or as a continuous variable showed
no associations with sepsis risk. However, LDL-C in the
lowest two quartiles was associated with increased
adjusted rates of sepsis. We observed a linear trend
across LDL-C quartiles (Figs. 1 and 2). We obtained
similar inferences when LDL-C was defined as a con-
tinuous variable or as a percentage of total cholesterol.
We observed similar results when stratifying by statin
use and redefining quartile cutoff values (Table 4).
Lastly, we observed similar associations when adjusting
for BMI, hs-CRP, Cystatin C, ACR, and eGFR as con-
tinuous variables. (Additional file 1: Table S1)
Discussion
In this large, prospective cohort study we have demon-
strated that baseline cholesterol levels may be associated
with long-term risk of sepsis. Specifically, we found that
lower LDL-C values, though generally accepted to be
favorable in terms of cardiovascular disease risk and
prevention of CAD, seem to be associated with increased
long-term risk of sepsis. Contrary to our original hy-
pothesis, we found no association between low HDL-C
and sepsis risk after adjusting for potential confounders.
In recent years, the bulk of sepsis research has focused
on early detection and care of acute sepsis. But few ef-
forts have conceptualized sepsis as a preventable condi-
tion. Identifying risk factors and developing a strategy
for sepsis prevention could be a worthwhile endeavor to
reduce the societal burden of this life-threatening and
costly disease. The results of this study have important,
yet perplexing implications for sepsis prevention. In the
cardiovascular literature, lower LDL-C (<130 mg/dl) and
higher HDL-C (>60 mg/dl) thresholds are thought to be
protective against CAD [1]. Our results, however, demon-
strate that lower LDL-C levels are associated with increased
long-term risk of sepsis. We have also demonstrated an
Table 1 Baseline participant characteristics by HDL-C and LDL-C quartile

























Number of participants 7305 7064 7162 6749 6984 7088 6915 6896
Demographics
Age (years), mean (SD) 64.8 (9.3) 64.8 (9.5) 64.8 (9.3) 65.1 (9.5) 66.3 (9.5) 65.4 (9.5) 64.5 (9.4) 63.4 (9.0)
Age group (%)
45–49 5.0 5.5 4.8 4.6 4.4 4.7 5.4 5.4
50–59 26.0 25.5 26.5 26.8 20.8 24.7 27.9 31.3
60–69 38.2 38.3 37.8 36.3 37.0 37.7 37.1 38.5
70–79 24.3 23.4 24.2 24.6 28.9 25.1 23.0 19.8
≥80 6.6 7.3 6.6 7.7 8.8 7.9 6.7 5.0
Gender (%)
Male 71.3 51.6 35.3 21.7 51.1 47.1 43.6 38.9
Female 28.7 48.4 64.7 78.3 48.9 52.9 56.4 61.1
Race (%)
White 67.6 58.8 55.7 55.5 62.3 61.3 58.6 54.6
Black 32.4 41.3 44.3 44.5 37.7 38.7 41.4 45.5
Education (%)
Less than high school 13.1 12.8 12.4 10.9 13.5 11.8 11.8 12.1
High school graduate 25.8 26.4 26.4 24.6 26.1 25.4 24.4 27.3
Some college 27.2 26.6 26.9 26.5 26.0 26.7 27.8 26.7
College or higher 34.0 34.2 34.3 38.1 34.5 36.2 36.1 33.9
Missing (N) 7 4 3 7 7 4 3 7
Income (%)
< $20,000 16.6 18.3 18.0 17.7 18.2 16.9 16.5 18.7
$20,000–34,000 24.0 24.0 24.9 23.5 25.2 24.0 22.9 24.4
$35,000–74,000 32.1 30.8 29.1 28.0 29.8 30.8 30.7 29.1
≥ $75,000 16.6 15.5 15.5 16.4 15.0 16.2 17.3 15.6
Refused 10.7 11.4 12.5 14.4 11.9 12.1 12.6 12.2
Geographic region (%)
Stroke buckle 20.7 20.6 21.7 20.9 22.4 20.7 20.4 20.2
Stroke belt 37.0 35.7 33.7 32.6 35.1 35.1 33.7 34.9
Nonbelt/buckle 42.3 43.7 44.7 46.5 42.5 44.2 46.0 44.9
Health behaviors
Smoking status (%)
Current 17.1 15.1 13.2 12.1 14.1 13.1 14.2 15.8
Past 44.9 41.1 38.3 37.1 44.4 40.9 39.1 36.9
Never 38.1 43.9 48.5 50.9 41.5 46.0 46.7 47.2
Missing (N) 17 29 31 28 23 24 31 25
Alcohol use (%)
Heavy 1.8 3.1 4.0 7.5 4.0 4.4 3.9 3.7
Moderate 31.8 32.5 33.5 36.7 32.3 35.0 34.8 32.0
None 66.4 64.4 62.5 55.9 63.7 60.6 61.3 64.3
Missing (N) 155 153 106 134 145 140 122 130
Guirgis et al. Critical Care  (2016) 20:408 Page 5 of 12
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Chronic medical conditions
Cancer (%) 10.3 8.5 8.0 8.0 10.2 9.3 8.0 7.2
Chronic lung disease (%) 8.3 9.2 9.2 10.0 10.7 9.7 8.8 7.4
Coronary artery disease (%) 25.3 19.2 15.1 11.5 28.7 18.7 12.9 10.7
Diabetes (%) 30.3 25.4 19.0 14.2 33.5 22.9 17.0 14.8
Hypertension (%) 63.5 60.8 58.0 53.7 67.0 60.2 55.9 52.3
Obesity (%) 61.7 57.2 53.6 40.0 54.5 52.0 52.3 54.0
Stroke (%) 7.6 7.0 5.7 4.4 8.5 6.3 5.0 4.9
Statin use (%) 35.3 35.2 31.6 23.6 56.6 47.0 36.8 37.0
Biomarkers
hs-CRP > 3.0 mg/dl 44.6 41.8 40.3 35.5 38.3 39.6 40.8 43.8
Missing (N) 148 165 167 179 150 177 159 160
Cystatin C > 1.12 mg/dl 34.1 26.7 21.6 17.3 32.1 25.7 22.2 19.7
Missing (N) 183 187 208 212 189 199 196 191
ACR > 30 μg/mg (%) 18.8 15.7 13.0 12.5 17.5 15.0 13.7 13.3
Missing (N) 267 308 249 254 295 287 227 250
eGFR < 60 ml/min/1.73 m2 14.7 11.8 10.3 8.7 15.2 11.9 9.7 8.8
Missing (N) 1 0 1 0 0 0 1 1
Functional status
Weakness (SF-12 PCS < 75) (%) 31.0 29.9 28.8 26.7 33.8 28.9 26.5 26.8
Reported exhaustion (%) 15.7 13.9 13.4 11.7 14.8 14.1 12.4 13.0
Low physical activity (%) 34.7 33.5 33.6 32.6 35.4 33.7 32.6 32.6
Total of 29,690 participants. LDL-C measurement missing for 1807 participants. HDL-C measurement missing for 1410 participants
All p < 0.05 based on Pearson chi-square tests of association
LDL-C low-density lipoprotein, HDL-C high-density lipoprotein, SD standard deviation, hs-CRP high-sensitivity C-reactive protein, ACR albumin–creatinine ratio,
eGFR estimated glomerular filtration rate, SF-12 12-item short form survey, PCS physical composite score
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SOFA scores.
Previous studies have demonstrated that low choles-
terol levels are a risk factor for sepsis [16, 30, 31] and
have also shown that lipid levels are rapidly changing dur-
ing early sepsis and may predict outcomes [12–14, 30, 31].
In the setting of infection, cholesterol levels may drop dra-
matically because of decreases in LDL-C and HDL-C. The
exact mechanism for this is unknown; however, bacterial
endotoxin, tumor necrosis factor, interleukin-2, and inter-
feron beta, all potentially present during systemic
infection, reduce serum cholesterol levels [32–37].
Additionally, both LDL-C and HDL-C play a proven role
in clearance of bacterial toxins, lipopolysaccharide (LPS)
from Gram-negative bacteria, and lipoteichoic acid from
Gram-positive bacteria. In studies where LPS was added
to human whole blood in vitro, LPS was bound to HDL-C
(60%), LDL-C (25%), and very low density lipoprotein
(VLDL)-cholesterol (12%) [38]. Therefore, one potential
explanation for the increased long-term sepsis risk with
low LDL-C is the inability to clear bacterial toxins from
the bloodstream.Interestingly, our study did not demonstrate an associ-
ation between low HDL-C and long-term sepsis risk. At
a glance, these results appear contrary to findings by
Chien et al. that low HDL-C levels in acute sepsis are
predictive of increased 30-day mortality, prolonged ICU
stay (> 7 days), and increased hospital-acquired
infections. However, there are two reasons why these
results should not be entirely surprising. First, recent
evidence has demonstrated that HDL-C function may be
more important than quantity. Examples include recent
clinical trials that failed to show benefit to medically
elevating HDL-C to prevent myocardial infarction [3].
Another recent Mendelian randomization study failed to
find a reduced risk of myocardial infarction in a group
of patients with a specific single nucleotide polymorph-
ism predisposing to elevated HDL-C [39]. These studies
are timely, given a burgeoning area of research demon-
strating that HDL-C can become dysfunctional and
proinflammatory under certain chronic (metabolic syn-
drome, diabetes mellitus, rheumatoid arthritis, CAD)
and acute (sepsis, myocardial infarction, stroke) inflam-
matory conditions [40–44]. HDL-C function may then
Table 2 Sepsis incidence rates and hospitalization characteristics by HDL-C and LDL-C quartile



























7305 7064 7162 6749 6984 7088 6915 6896
Sepsis events, N (%) 485 (6.6) 372 (5.3) 329 (4.6) 264 (3.9) 451 (6.5) 399 (5.6) 304 (4.4) 261 (3.8)
IR (per 1000
person-years), 95% CI
10.6 (9.7–11.6) 8.5 (7.7–9.4) 7.3 (6.6–8.1) 6.2 (5.5–7.0) 10.6 (9.6–11.6) 8.9 (8.1–9.9) 6.9 (6.2–7.7) 6.0 (5.3–6.8)
Sepsis event hospitalization characteristics
Infection type, N (%)




86 (17.7) 71 (19.1) 58 (17.6) 22 (12.5) 0.16 80 (17.7) 79 (19.8) 61 (20.1) 22 (8.4) <0.001
Abdominal 78 (16.1) 71 (19.1) 40 (12.2) 22 (12.5) 0.038 62 (13.8) 64 (16.0) 44 (14.5) 47 (18.0) 0.45
Skin and soft
tissue





34 (7.0) 34 (9.1) 35 (10.6) 31 (11.7) 0.13 34 (7.5) 38 (9.5) 34 (11.2) 27 (10.3) 0.35
Sepsis 42 (8.7) 21 (5.7) 18 (5.5) 16 (6.1) 0.20 30 (6.7) 23 (5.8) 16 (5.3) 24 (9.2) 0.24
Fever of
unknown origin
4 (0.8) 7 (1.9) 11 (3.3) 4 (1.5) 0.072 6 (1.3) 9 (2.3) 3 (1.0) 7 (2.7) 0.34
Surgical wound 1 (0.2) 3 (0.8) 5 (1.5) 1 (0.4) 0.14 2 (0.4) 2 (0.5) 2 (0.7) 4 (1.5) 0.41
Catheter (IV/
central/dialysis)
2 (0.4) 0 (0) 0 (0) 3 (1.1) – 2 (0.4) 1 (0.3) 1 (0.3) 0 (0) 0.91
Meningitis 0 (0) 2 (0.5) 2 (0.6) 1 (0.4) 0.27 2 (0.4) 1 (0.3) 0 (0) 2 (0.8) 0.51
Unknown/other 9 (1.9) 6 (1.6) 5 (1.5) 2 (0.8) 0.70 9 (2.0) 5 (1.3) 4 (1.3) 4 (1.5) 0.85
Elevated SOFA score
(SOFA≥ 2), N (%)
266 (54.9) 175 (47.0) 147 (44.7) 119 (45.1) 0.010 251 (55.7) 201 (50.4) 127 (41.8) 107 (41.0) <0.001
Admitted to ICU vs
floor, N (%)a
69 (16.0) 42 (12.8) 41 (14.4) 24 (9.9) 0.16 70 (17.0) 41 (11.6) 26 (10.2) 32 (13.9) 0.051
In-hospital death,
N (%)
43 (8.9) 30 (8.1) 30 (9.1) 25 (9.5) 0.93 43 (9.5) 35 (8.8) 19 (6.3) 29 (11.1) 0.22
Total of 29,690 participants. LDL-C measurement missing for 1807 participants. HDL-C measurement missing for 1410 participants
p values from Pearson chi-square tests of association for variables with at least five observations in 75% of table cells, and Fisher exact tests for all others
aIncludes only events resulting in an inpatient admission and those with inpatient records available
LDL-C low-density lipoprotein, HDL-C high-density lipoprotein, IR incidence rate, CI confidence interval, SOFA Sepsis-related Organ Failure Assessment,
ICU intensive care unit
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given the prevalence of chronic inflammatory condi-
tions within the REGARDS cohort. Another explan-
ation may be the difference between rapid lowering of
lipid levels during acute inflammatory states which
relate to disease severity, rather than chronically low
levels of HDL-C which, if dysfunctional, may not protect
as well against sepsis. In order to address this question,
future studies aimed at prospectively measuring dysfunc-
tional HDL and monitoring for the development of sepsis
are needed.Potential clinical applications for the results of this
study may include modulation of LDL clearance.
Lipid-based pathogens from bacteria are first bound
to binding proteins which are then bound by HDL
and transferred to LDL or VLDL molecules. LDL and
VLDL are then cleared from the bloodstream by he-
patocytes via the LDL receptor. The proprotein con-
vertase subtilisin/kexin type 9 (PCSK9) molecule
binds the LDL receptor on hepatocytes, and promotes
internalization and lysosomal degradation of the re-
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Fig. 1 Adjusted Kaplan–Meier (KM) failure curves for time to sepsis by HDL-C and LDL-C quartiles (Q1 = lowest quartile, Q4 = highest quartile).
Total of 29,690 participants. (a) High-density lipoprotein cholesterol (HDL-C) and (b) low-density lipoprotein cholesterol (LDL-C). All failure functions
estimated among White, female, nonsmoking and non-alcohol-consuming participants residing in the nonbelt region, with no history of comorbidities,
normal biomarker levels, and no functional status impairments (all binary variables set to zero and all categorical variables set to the reference groups)
Guirgis et al. Critical Care  (2016) 20:408 Page 9 of 12from the blood [45]. PCSK9 inhibitors are currently
under investigation as lipid-lowering agents because
they promote LDL clearance and thus reduce LDL
levels, but they may also have an application in clear-
ance of lipid-based pathogens in sepsis. PCSK9 inhib-
ition results in decreased inflammatory cytokine
production and physiological responses to endotoxin
in septic mice and increased PCSK9 levels are associ-
ated with reduced endotoxin clearance and organ
failure in sepsis [45, 46]. Although this is a new area
of research, it demonstrates that modulation of chol-
esterol metabolism may have potential as a future ap-
plication of these findings. In addition, because HDL
plays a critical intermediary step in lipid-based
pathogen clearance, investigating HDL function in
sepsis is of increased importance. If the association
between HDL-C and sepsis-associated organ dysfunc-
tion is valid, studies of HDL-based therapies includ-
ing apoliprotein mimetic peptides and synthetic HDL
may hold potential [47, 48].
In our analysis, we chose to stratify by baseline sta-
tin use, because statins have had significant attention
in the literature with regards to protection against
sepsis. The mechanisms by which statins may protect
against sepsis are unknown, though a new class of
lipid mediators called resolvins may play a role [49].
Also, varying protection against sepsis has been found
between different statins, with atorvastatin being the
most promising [50]. Our group completed a recent
study which did not find baseline statin use to be
protective against long-term sepsis in the REGARDS
cohort [51]. In addition, statin use did not signifi-
cantly influence our results with regards to baseline
lipid levels. Two recent meta-analyses of only ran-
domized, controlled trials also found no benefit to
statin use in sepsis [52, 53].This study had several limitations. Only baseline
lipid levels were available for analysis, there were no
repeat levels or levels prior to the sepsis event.
Therefore, lipid levels may have changed over time
prior to the sepsis event, though we feel that the
magnitude of change would have been unlikely to
change our results. REGARDS was not designed to
study sepsis, and therefore some sepsis events could
have been missed. However, given the systematic hos-
pital record review, we believe we have minimized the
potential for missed or wrongly identified cases of
sepsis. The REGARDS cohort only includes Black and
White participants at least 45 years of age, and there-
fore results may not be as generalizable to other eth-
nic groups or a younger population. Sepsis events
were limited to community-acquired sepsis and did
not include hospital-acquired sepsis events, because
hospital sepsis is more likely to be influenced by multiple
factors related to the hospitalization. Also, while we made
every effort to adjust for potential confounders, other vari-
ables such as vaccination or access to healthcare which
were not accounted for may have influenced the results.
Finally, residual confounding is a potential concern, as
with any observational study. We accounted for a compre-
hensive range of variables through our risk adjustment
strategy for each participant at the beginning of the
REGARDS study, but we could not account for changes in
these patterns over time.
Conclusions
In this large, prospective cohort study, low LDL-C
was associated with increased long-term rates of
community-acquired sepsis. HDL-C was not associated
with long-term sepsis. Future studies should attempt to
characterize the pathophysiologic or mechanistic basis for
these associations.
Fig. 2 Risk of sepsis by HDL-C or LDL-C quartile (Q1 = lowest quartile, Q4 = highest quartile). LDL-C low-density lipoprotein, HDL-C high-density
lipoprotein, HR hazard ratio, CI confidence interval
Table 4 Associations of HDL-C and LDL-C with sepsis rates stratified by statin use
Variable Total N Sepsis events, Sepsis incidence
(per 1000 person-years),
Models for sepsis hazard
Unadjusted, Adjusteda,
N (%) IR (95% CI) HR (95% CI) HR (95% CI)
Statin non-users
HDL-C quartile
Q1 (5–41 mg/dl) 5233 315 (6.0) 9.6 (8.6–10.7) 1.73 (1.43–2.09) 1.09 (0.88–1.36)
Q2 (42–50 mg/dl) 4540 223 (4.9) 7.9 (6.9–9.0) 1.43 (1.16–1.76) 1.11 (0.89–1.37)
Q3 (51–62 mg/dl) 4751 201 (4.2) 6.8 (5.9–7.8) 1.21 (0.98–1.49) 1.06 (0.86–1.31)
Q4 (63–199 mg/dl) 4837 169 (3.5) 5.5 (4.8–6.4) Reference Reference
Trend p value <0.001 0.44
LDL-C quartile
Q1 (3–99 mg/dl) 4816 278 (5.8) 9.4 (8.3–10.5) 1.54 (1.28–1.86) 1.32 (1.10–1.60)
Q2 (100–120 mg/dl) 4810 231 (4.8) 7.6 (6.7–8.7) 1.29 (1.06–1.57) 1.19 (0.98–1.46)
Q3 (121–143 mg/dl) 4842 212 (4.4) 6.9 (6.0–7.9) 1.13 (0.93–1.37) 1.11 (0.91–1.36)
Q4 (144–388 mg/dl) 4619 169 (3.7) 5.8 (5.0–6.8) Reference Reference
Trend p value <0.001 0.003
Statin users
HDL-C quartile
Q1 (11–39 mg/dl) 2304 170 (7.4) 11.8 (10.2–13.7) 1.37 (1.08–1.73) 0.89 (0.69–1.17)
Q2 (40–47 mg/dl) 2274 134 (5.9) 9.6 (8.1–11.4) 1.11 (0.87–1.43) 0.87 (0.67–1.13)
Q3 (48–57 mg/dl) 2163 119 (5.5) 8.8 (7.3–10.5) 1.03 (0.80–1.33) 0.93 (0.72–1.20)
Q4 (58–156 mg/dl) 2178 119 (5.5) 8.7 (7.3–10.4) Reference Reference
Trend p value 0.006 0.39
LDL-C quartile
Q1 (11–76 mg/dl) 2210 175 (7.9) 13.1 (11.3–15.1) 2.00 (1.55–2.59) 1.50 (1.14–1.96)
Q2 (77–93 mg/dl) 2304 142 (6.2) 9.9 (8.4–11.7) 1.55 (1.19–2.03) 1.36 (1.03–1.78)
Q3 (94–111 mg/dl) 2091 127 (6.1) 9.6 (8.1–11.4) 1.49 (1.13–1.96) 1.38 (1.04–1.81)
Q4 (112–315 mg/dl) 2191 81 (3.7) 5.9 (4.7–7.3) Reference Reference
Trend p value <0.001 0.008
Total of 29,690 REGARDS participants. HRs estimated using Cox proportional hazards regression and represent pooled estimates from multiple imputation
p values represent tests for linear trends across quartiles
aAdjusted for demographics, health behaviors, chronic medical conditions, biomarkers, and functional status measures. Demographics = age, gender, race, region,
income, and education; health behaviors = smoking status and alcohol use; chronic medical conditions = cancer, chronic lung disease, coronary artery disease,
diabetes, hypertension, obesity, stroke, and Morisky medication adherence index; biomarkers = hs-CRP, Cystatin C, ACR, and eGFR; functional status measures =weakness,
exhaustion, and low physical activity
HR hazard ratio, IR incidence rate, CI confidence interval, LDL-C low-density lipoprotein, HDL-C high-density lipoprotein, hs-CRP high-sensitivity C-reactive protein,
ACR albumin–creatinine ratio, eGFR estimated glomerular filtration rate
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Additional file 1: Table S1. Is presenting results analyzed using a
nonimputed data set. *Adjusted for demographics, health behaviors,
chronic medical conditions, biomarker values, and functional status
measures. Demographics = age, gender, race, region, income, and
education; health behaviors = smoking status and alcohol use; chronic
medical conditions = cancer, chronic lung disease, coronary artery
disease, diabetes, hypertension, obesity, stroke, and Morisky medication
adherence index; biomarkers = hs-CRP, Cystatin C, ACR, and eGFR;
functional status measures = weakness, exhaustion, and low physical
activity. HR hazard ratio, CI confidence interval, LDL-C low-density
lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol,
hs-CRP high-sensitivity C-reactive protein, ACR albumin–creatinine ratio,
eGFR estimated glomerular filtration rate. (DOCX 12 kb)Abbreviations
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